Literature DB >> 11165398

Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor.

E Toyoshima1, Y Ohsaki, Y Nishigaki, Y Fujimoto, Y Kohgo, K Kikuchi.   

Abstract

In order to determine syndecan-1 expression in lung cancer, we examined 115 lung cancer specimens and 17 lung cancer cell lines. Syndecan-1 was immunohistochemically stained with a polyclonal antibody in 115 paraffin-embedded specimens; 84 cases out of 97 non-small cell lung cancer (NSCLC) and eight cases out of 18 small cell lung cancer (SCLC) were positively stained. Simultaneously, epidermal growth-factor receptor (EGFR) was stained; 47 cases out of 97 NSCLC and one case of 18 SCLC were positively stained. No significant correlation was shown between EGFR and syndecan-1 expression (P=0.68). Syndecan-1 mRNA was detectable in 16 of 17 lung cancer cell lines and EGFR mRNA in nine of 17. Eight cell lines had syndecan-1 mRNA as well as EGFR mRNA. PR-39 (1 microM) and 80 pM transforming growth factor-beta(1) (TGF-beta(1)), did not increase expressions of syndecan-1 mRNA and EGFR in five lung cancer cell lines. We concluded that lung cancer had detectable syndecan-1; however, expression of syndecan-1 protein did not correlate with survival time of lung cancer patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11165398     DOI: 10.1016/s0169-5002(00)00184-7

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  8 in total

1.  Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression.

Authors:  Arata Watanabe; Tadashi Mabuchi; Eiji Satoh; Koro Furuya; Lei Zhang; Shuichiro Maeda; Hirofumi Naganuma
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

2.  E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy.

Authors:  Pinelopi Gkogkou; Evangelia Peponi; Dimitrios Ntaskagiannis; Samuel Murray; Asimo Demou; Ioannis Sainis; Elli Ioakeim; Evangelos Briasoulis; Pericles Tsekeris
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

3.  Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression method.

Authors:  Hongying Du; Zhide Hu; Andrea Bazzoli; Yang Zhang
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

Review 4.  Dually modified transmembrane proteoglycans in development and disease.

Authors:  Laura M Jenkins; Ben Horst; Carly L Lancaster; Karthikeyan Mythreye
Journal:  Cytokine Growth Factor Rev       Date:  2017-12-22       Impact factor: 17.660

Review 5.  Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.

Authors:  Tünde Szatmári; Rita Ötvös; Anders Hjerpe; Katalin Dobra
Journal:  Dis Markers       Date:  2015-09-01       Impact factor: 3.434

Review 6.  EGFR-Dependent Extracellular Matrix Protein Interactions Might Light a Candle in Cell Behavior of Non-Small Cell Lung Cancer.

Authors:  Sarah Sayed Hassanein; Ahmed Lotfy Abdel-Mawgood; Sherif Abdelaziz Ibrahim
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

7.  Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments.

Authors:  Xufan Li; Jia Li; Pin Wu; Liyuan Zhou; Bingjian Lu; Kejing Ying; Enguo Chen; Yan Lu; Pengyuan Liu
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

8.  Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.

Authors:  Simon Kind; Christina Merenkow; Franziska Büscheck; Katharina Möller; David Dum; Viktoria Chirico; Andreas M Luebke; Doris Höflmayer; Andrea Hinsch; Frank Jacobsen; Cosima Göbel; Sören Weidemann; Christoph Fraune; Christina Möller-Koop; Claudia Hube-Magg; Till S Clauditz; Ronald Simon; Guido Sauter; Waldemar Wilczak; Ahmed Abdulwahab Bawahab; Jakob R Izbicki; Daniel Perez; Andreas Marx
Journal:  Dis Markers       Date:  2019-12-23       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.